Diagnostics Stocks Ranked: 5 Names Trading at 4x to 15x

Every biotech investor has watched a stock implode 40 percent on a Phase 3 failure. The drug missed its endpoint, the company burned $400 million, and shareholders got nothing. Diagnostics companies invert that risk. They sell the tests, not the cures. No PDUFA coin-flip. No single-arm Phase 1 hype. Just labs processing samples and billing insurers, quarter after quarter, growing with test volume and ASP expansion.

That thesis is correct. But by July 2026, the market has priced it in with a sledgehammer. Natera trades at 13x revenue. Guardant trades at 14.6x. Exact Sciences trades at 6.4x. The diagnostics trade is crowded, and the entry points are brutal. If you want the biotech picks and shovels exposure without the PDUFA coin-flip, you need to know which of these five names actually justifies its multiple and which is running on fumes.

The companion diagnostics market is growing at 12.9 percent CAGR, projected to reach $11.6 billion by 2031 from $6.3 billion in 2026, according to MarketsandMarkets. Precision medicine is a $135 billion market in 2026 growing at 17 percent annually. Every targeted therapy approval pulls a companion diagnostic along with it. That is the structural tailwind. The question is whether the current valuations already discount the next decade of growth.

Natera (NTRA): $252.22 | Market Cap $36.1B | The Category Leader at a Premium Price

Natera is the unambiguous leader in circulating tumor DNA (ctDNA) testing for minimal residual disease (MRD) detection. The Signatera test holds approximately 80 percent of the US MRD testing market. Q1 2026 results tell the growth story: total revenue of $696.6 million, up 39 percent year over year. The company processed 1,013,600 tests in the quarter, up 18.5 percent. Oncology tests specifically hit 258,900, up 54.4 percent from 167,700 in Q1 2025. Gross margin expanded to 64.7 percent, and 2026 full-year revenue guidance is $2.74 to $2.82 billion.

Signatera ASPs have climbed to $1,250 per test, with management guiding to an exit rate of $1,275 by year-end. The ASP expansion matters because it signals pricing power in a market where CMS reimbursement cuts are the existential risk. Natera is growing test volume 54 percent and raising prices simultaneously. That combination is rare in diagnostics, where most companies face ASP compression.

But $36.1 billion market cap against $2.78 billion in guided revenue is a 13x price-to-sales ratio. For comparison, Exact Sciences trades at 6.4x revenue with a broader colorectal cancer screening franchise. Natera’s premium is justified by its 54 percent oncology growth rate and expanding margins, but it leaves zero room for a reimbursement surprise. If CMS cuts Signatera reimbursement by 15 percent, the stock loses 25 percent on the multiple compression alone. That is the binary risk in diagnostics: not trial failure, but a Medicare fee schedule update.

Guardant Health (GH): $143.62 | Market Cap $19.0B | The Liquid Biopsy Challenger Growing Faster Than Natera

Guardant is the number two liquid biopsy player, and it is growing faster. Q1 2026 revenue was $301.7 million, up 48 percent year over year, beating Street estimates by 8.4 percent. The company raised 2026 full-year guidance to $1.30 to $1.32 billion. Guardant’s growth is driven by both oncology (therapeutic and screening) and its Shield colorectal cancer screening test, which received Medicare coverage in 2025.

At $19.0 billion market cap against $1.31 billion in guided revenue, Guardant trades at 14.6x sales. That is a 13 percent premium to Natera’s P/S ratio despite Guardant having lower gross margins. Guardant’s Q1 gross margin was approximately 68 percent, slightly ahead of Natera’s 64.7 percent but on a much smaller revenue base. The bullish case is that Guardant’s Shield screening test opens a TAM far larger than MRD monitoring: colorectal cancer screening, with 15 million Americans eligible annually. The bear case is that Guardant is losing the oncology MRD battle to Natera’s 80 percent market share and is betting the company on screening volume ramping before cash runs out.

Guardant had $662 million in cash and equivalents at the end of 2025. At the current burn rate, that runway extends through 2027. The company needs to reach profitability before the cash runs out, and the 48 percent revenue growth is the evidence that it can. But a 14.6x sales multiple on a company that is not yet profitable is a aggressive bet on execution.

Exact Sciences (EXAS): $104.91 | Market Cap $20.0B | The Screening Incumbent Growing at Half the Rate

Exact Sciences owns Cologuard, the dominant non-invasive colorectal cancer screening test. Q2 2025 revenue was $811 million, up 16 percent year over year. Full-year 2025 revenue exceeded $3.1 billion. The company provides 2026 guidance of $3.07 to $3.12 billion, implying roughly 11 percent growth.

At $20.0 billion market cap against approximately $3.1 billion in revenue, EXAS trades at 6.4x sales. That is half of Natera’s multiple and less than half of Guardant’s. The discount reflects two things: Cologuard growth is decelerating to mid-teens from the 20+ percent rates of 2023-2024, and Exact Sciences faces direct competition from Guardant’s Shield blood-based test, which is easier for patients (blood draw versus stool sample) and now has Medicare coverage.

Exact Sciences is the value play in diagnostics. It is profitable, growing 11-16 percent, and trades at a 50 percent discount to its peers on a P/S basis. The risk is that Guardant’s Shield cannibalizes Cologuard’s market share over the next 2-3 years. If 10 percent of Cologuard’s volume shifts to Shield, Exact Sciences loses $300 million in annual revenue and the multiple compresses further.

Lantheus (LNTH): $102.64 | Market Cap $6.68B | The Imaging Agent Value Play With a CRL Problem

Update August 22, 2026: Two developments have superseded the Lantheus thesis below. The FDA approved Lantheus’s MK-6240 (now branded TAUKLARIFY) on August 14 — the second tau PET imaging agent ever cleared for Alzheimer’s disease — see our TAUKLARIFY analysis. Separately, Curium agreed August 3 to acquire Lantheus for $102.50 per share in cash plus up to $12 in contingent value rights. The stock is now a merger-arbitrage position pinned within a few points of the $102.50 deal price, not a value play on the declining PYLARIFY franchise. The “Avoid” verdict below reflects the pre-deal fundamentals; it has been overtaken by the buyout and the tau approval.

Lantheus is the odd one out. The other four companies sell tests. Lantheus sells PET imaging agents, which are drugs, not tests. That means FDA approval, manufacturing inspections, and the full regulatory gauntlet. LNTH-2501, a Gallium-68 edotreotide kit for imaging somatostatin receptor-positive neuroendocrine tumors, received a Complete Response Letter on June 26, 2026. The CRL was for third-party manufacturing facility issues, not efficacy or safety. The drug works. The factory does not. We covered what a CRL means for investors in a separate piece; the key takeaway is that manufacturing CRLs are fixable but unpredictable.

Q1 2026 revenue was $377.3 million, up just 1.2 percent year over year. PYLARIFY, the PSMA PET imaging agent for prostate cancer that is Lantheus’s lead product, generated $240.9 million in Q1, down 6.5 percent from $257.7 million a year earlier. PYLARIFY is facing generic competition from Ga-68 PSMA-11, which is available at no cost at certain academic centers. That is a structural headwind that will compress PYLARIFY revenue for the foreseeable future.

2026 full-year guidance is $1.4 to $1.45 billion. At $6.68 billion market cap, Lantheus trades at 4.6x sales, the cheapest multiple in the group. But you are paying 4.6x a declining revenue stream. PYLARIFY is shrinking. LNTH-2501 is delayed by a CRL with no timeline for resolution. The pipeline has MK-6240, a tau PET imaging agent for Alzheimer’s partnered with Merck, but that is early-stage. Lantheus is cheap for a reason: the core business is decelerating and the pipeline is stalled.

Illumina (ILMN): $192.98 | Market Cap $29.2B | The Picks and Shovels of the Picks and Shovels

Illumina does not sell tests. It sells the sequencers that every diagnostics company uses to run genomic tests. NovaSeq X placements exceeded expectations in Q1 2026, and Illumina raised full-year guidance to $4.52 to $4.62 billion. The company reports Q2 2026 on July 30, tomorrow, which will be the next major catalyst for the stock.

At $29.2 billion market cap against $4.57 billion in guided revenue, Illumina trades at 6.4x sales, in line with Exact Sciences. But Illumina’s growth rate is slower: the company grew revenue approximately 5-7 percent in 2025 after a multi-year contraction following the Grail acquisition and divestiture. The thesis for Illumina is not growth. It is that every new diagnostics company that launches a genomic test buys Illumina sequencers. Natera’s 54 percent oncology volume growth means more sequencing reagent revenue for Illumina. Guardant’s 48 percent growth means the same.

The risk for Illumina is competition from Element Biosciences and Ultima Genomics, both of which are shipping next-generation sequencers at lower price points. Illumina’s moat is its installed base and bioinformatics ecosystem, but the hardware margin is under pressure. Illumina is the ultimate picks and shovels play, but it is a slow-growth picks and shovels play trading at a fair multiple.

The Verdict: Where to Put Your Money

Ranked by risk-reward at current prices:

1. Exact Sciences (EXAS) | 6.4x sales | Watch. The cheapest multiple in the group, profitable, and the incumbent in colorectal screening. The Guardant Shield threat is real but will take 2-3 years to materialize. At 6.4x sales, you are not paying for growth you are paying for the existing cash flow. That is the safest entry point in diagnostics.

2. Natera (NTRA) | 13x sales | Hold. The best company in the group with the worst entry point. 54 percent oncology growth and margin expansion are real. 13x revenue prices in five years of perfect execution. If you own it, hold. If you do not, wait for a CMS reimbursement scare to buy at a discount.

3. Guardant Health (GH) | 14.6x sales | Watch, do not chase. 48 percent growth is impressive but the company is unprofitable and the Shield ramp is unproven at scale. The valuation requires everything to go right. If Shield volume misses in Q2 or Q3 2026, the stock corrects 20 percent.

4. Illumina (ILMN) | 6.4x sales | Hold. A slow-growth platform company at a fair multiple. The Q2 2026 earnings report on July 30 is the near-term catalyst. If NovaSeq X placements accelerate, the stock re-rates. If Element Biosciences takes share, it does not.

5. Lantheus (LNTH) | Merger arb, not a value play. Since publication, the FDA approved TAUKLARIFY (MK-6240) on August 14 — the second tau PET tracer ever cleared — and Curium agreed to acquire Lantheus at $102.50 per share. The stock now trades within a few points of the $102.50 deal price. The original “Avoid” call was about a declining core business; that thesis has been overtaken by the buyout, which sets the price in cash.

The contrarian call: everyone in diagnostics is buying Natera and Guardant because the growth rates are undeniable. The real opportunity is Exact Sciences at half the multiple, with the same revenue base and profitability, facing a competitive threat that is already known and priced in. The market is paying 13x for 54 percent growth at Natera and 6x for 16 percent growth at Exact Sciences. The best biotech stocks ranking prioritizes catalyst density. Diagnostics is the opposite play: lower binary risk, but you need to buy the right multiple, not the fastest growth rate.